Compare UnitedHealth Group Incorporated (UNH) vs Agios Pharmaceuticals, Inc. (AGIO) Stock

UnitedHealth Group Incorporated (UNH) offers the better valuation at 18.8x trailing P/E (16.4x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, UnitedHealth Group Incorporated (UNH) delivered a total return of -1.5%, compared to -36.4% for Agios Pharmaceuticals, Inc. (AGIO). A $10,000 investment in UNH five years ago would be worth approximately $10K today (assuming dividends reinvested). Over 10 years, the gap is even starker: UNH returned +191.5% versus AGIO's -21.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), UnitedHealth Group Incorporated (UNH) is the lower-risk stock at 0.28β versus Agios Pharmaceuticals, Inc.'s 0.91β — meaning AGIO is approximately 223% more volatile than UNH relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.

UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 3.2% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 3.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4.2% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AGIO: 37.3% to $41.50.

In this comparison, UNH (5.2% yield) pays a dividend. AGIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.28), 5.2% yield, +191.5% 10Y return). Both have compounded well over 10 years (UNH: +191.5%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: UNH is a large-cap income-oriented stock; AGIO is a mega-cap quality compounder stock. UNH pays a dividend while AGIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.